Researchers reported mechanistic work identifying GALE as a tumor-intrinsic checkpoint limiting Vγ9Vδ2 T-cell killing, following a genome-wide CRISPR screen in mouse models and patient-derived organoids. The finding suggests that metabolic enzymes within tumor cells can throttle effector-cell function, offering a new axis for sensitizing tumors to this specific T-cell subtype. In parallel, other preclinical immuno-oncology studies described additional molecular levers affecting therapy response—such as chromatin and metabolism reprogramming via SMARCAL1 condensates, which can weaken both radiotherapy and immunotherapy responses. Together, the work reinforces that resistance is increasingly being mapped not only to signaling pathways, but also to metabolic state and nuclear organization. For developers, the key action is target prioritization: metabolic checkpoints and chromatin-linked vulnerabilities can reshape combination strategies, but they will likely require careful translation plans to demonstrate controllable benefit in vivo.